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https://doi.org/10.1016/j.celrep.2021.109430SUMMARYWhile the intrinsic apoptosis pathway is thought to play a central role in shaping the B cell lineage, its precise
role in mature B cell homeostasis remains elusive. Using mice in which mature B cells are unable to undergo
apoptotic cell death, we show that apoptosis constrains follicular B (FoB) cell lifespan but plays no role in mar-
ginal zone B (MZB) cell homeostasis. In thesemice, FoB cells accumulate abnormally. This intensifies intercel-
lular competition for BAFF, resulting in a contraction of the MZB cell compartment, and reducing the growth,
trafficking, and fitness of FoB cells. Diminished BAFF signaling dampens the non-canonical NF-kB pathway,
undermining FoB cell growth despite the concurrent triggering of a protective p53 response. Thus, MZB and
FoB cells exhibit a differential requirement for the intrinsic apoptosis pathway. Homeostatic apoptosis con-
strains the size of the FoB cell compartment, thereby preventing competition-induced FoB cell atrophy.INTRODUCTION
B lymphocytes are the cellular basis of humoral immunity in
higher vertebrates. Two types of mature B lymphocytes are
found in mice: B1 cells, which are predominantly located in the
peritoneal and pleural cavities, and B2 cells, which reside in sec-
ondary lymphoid organs. Mature B2 cells are composed of follic-
ular B (FoB) cells and marginal zone B (MZB) cells, which both
arise from transitional B cells, a short-lived, bone marrow
(BM)-derived population. In the mouse, FoB cells are circulating
cells that live for3 months (Förster and Rajewsky, 1990; Rolink
et al., 1998) and reside within follicles in the spleen, lymph nodes
(LNs), and Peyer’s patches. In contrast, MZB cells are sessile,
residing in the outer white pulp of the spleen, (Pillai et al., 2005)
and they have been proposed to live as long as the host (Hao
and Rajewsky, 2001).
Under homeostatic conditions, mature B cell numbers in the
mouse are kept relatively constant (Crowley et al., 2008). EachThis is an open access article under the CC BY-Nday, transitional cells enter the pool of mature B cells, replacing
(presumably) senescent and/or functionally expended cells that
have been cleared. However, the mechanism(s) that regulate the
lifespan and clearance ofmature B cells in vivo remain somewhat
ill-defined. While intrinsic apoptosis (for simplicity referred to
hereafter as ‘‘apoptosis’’) is thought to play a central role in
lymphoid homeostasis, its precise functional contribution in
mature B cell homeostasis has never been defined.
The critical step in apoptosis is the activation of two pro-death
effector molecules, BAX and BAK, which form pores in the mito-
chondrial outer membrane, releasing cytochrome c (Youle and
Strasser, 2008). This triggers the apoptotic caspase cascade
and cell death. In healthy cells, the suppression of apoptotic ac-
tivity depends on the pro-survival members of the BCL-2 protein
family (BCL-2, BCL-XL, BCL-W, MCL-1, and A1), which can
physically bind to BAX and BAK, thereby restraining their pro-
death activity (Lee et al., 2016). Upon exposure to cellular stress,




OPEN ACCESSBIM, BMF, BAD, BID, HRK, and BIK) are increased and initiate
cell death signaling. BH3-only proteins do this by either binding
to the pro-survival BCL-2 family members, thereby unleashing
BAX and BAK, or by directly activating BAX and BAK (Giam
et al., 2008). Cells lacking both BAX and BAK are resistant to
pro-apoptotic stimuli; they do not exhibit cytochrome c release
or caspase activation, and they are able to maintain clonogenic-
ity (i.e., they can survive and generate viable progeny) (Ke et al.,
2018; Lindsten and Thompson, 2006; Wei et al., 2001).
The notion that apoptosis plays an essential role in lymphoid
homeostasis dates back to the discovery that the t(14;18) trans-
location (which deregulates BCL-2 expression) is found at high
incidence in follicular lymphoma (Tsujimoto et al., 1984) and
that BCL-2 overexpression confers increased survival capacity
(Vaux et al., 1988) and promotes tumorigenesis (Strasser et al.,
1990). Decades of research point to a critical role for apoptosis
in regulating B cell ontogeny. It is thought to underpin the elimi-
nation of cells that have failed to productively recombine the
immunoglobulin (Ig) gene locus (Strasser et al., 1994), have
assembled a self-reactive B cell receptor (Enders et al., 2003),
or have received insufficient cytokine signals (Maraskovsky
et al., 1997; Opferman, 2008; Strasser, 2005; Strasser et al.,
2008). The idea that apoptosis underpins B cell homeostasis is
further supported by the abnormal accumulation of B lympho-
cytes in mice whose B cell lineage is rendered resistant to
apoptosis (Lindsten et al., 2000; McDonnell et al., 1989; Strasser
et al., 1990, 1991a; Takeuchi et al., 2005). However, in these
mice, the entire lineage (from the progenitor stage onward)
was unable to undergo apoptosis, complicating the interpreta-
tion of the findings. While early studies demonstrated that resis-
tance to apoptosis protect B cells from cell death for extended
periods in vitro (Lindsten et al., 2000; McDonnell et al., 1989;
Strasser et al., 1990, 1991a, Takeuchi et al., 2005), it is still not
clear to what extent it regulates mature B cell lifespan in vivo.
Moreover, while it has been known for 3 decades that
apoptosis-resistant FoB cells are smaller in size relative to
wild-type (WT) cells in vivo (Sakai et al., 2009; Strasser et al.,
1990, 1991b), the underlying mechanism and the significance
of this observation have yet to be understood. Furthermore,
the MZB cell compartment is reduced in mice in which the B
cell lineage cannot undergo apoptosis (Sakai et al., 2009; Take-
uchi et al., 2005), a counterintuitive result yet to be fully explored.
Two crucial signals regulate mature B cell survival: those
emanating from the B cell antigen receptor (BCR) (Lam et al.,
1997), and those transduced through the receptor for the tumor
necrosis factor-family member, B cell-activating factor (BAFF).
Patients carrying mutations in the gene encoding BAFF receptor
(BAFF-R) suffer from B lymphopenia and agammaglobulinemia
and exhibit impaired humoral immune responses (Smulski and
Eibel, 2018; Warnatz et al., 2009), illustrating the essential role
of BAFF in B cell homeostasis. Inmice, the loss of BAFF signaling
does not perturb B lymphopoiesis in the BM, but severely de-
creases the numbers of transitional, FoB, and MZB cells (Sasaki
et al., 2004; Schiemann et al., 2001; Shulga-Morskaya et al.,
2004). The homeostatic role of BAFF in B cells is linked to its
pro-survival activity in peripheral B cells. Mature B cells fail to
survive in the absence of BAFF-R signaling, both in vitro or in vivo
(Rauch et al., 2009; Rolink et al., 2002; Woodland et al., 2008),2 Cell Reports 36, 109430, July 20, 2021and a spontaneous mutation in the gene encoding BAFF-R
severely truncates the lifespan of FoB cells (Harless et al., 2001).
BAFF is thought to promote B cell survival by antagonizing
apoptosis (Opferman, 2008; Strasser, 2005). BAFF increases
the expression of pro-survival MCL-1, BCL-2, BCL-XL, and A1
in B cells (Do et al., 2000; Hsu et al., 2002; Jacque et al., 2015;
Woodland et al., 2008) and reduces that of pro-apoptotic BAK
and BIM (Craxton et al., 2005; Do et al., 2000). This anti-
apoptotic activity has also been linked to lymphoid malig-
nancies, as it is produced in an autocrine fashion by non-Hodg-
kin lymphoma, chronic lymphocytic leukemia, and multiple
myeloma cells and protects malignant cells from apoptosis
in vitro (He et al., 2004; Kern et al., 2004; Moreaux et al., 2004;
Novak et al., 2002, 2004). However, BAFF is likely to exert func-
tions beyond blocking apoptosis, as BCL-2 overexpression
cannot rescue mature B cell compartments in mice in which
BAFF-R signaling is disrupted (Rahman and Manser, 2004; Sa-
saki et al., 2004; Tardivel et al., 2004). These data are difficult
to interpret, because, on the one hand, BCL-2 overexpression
may not completely suppress BAX and BAK activity, and on
the other hand, BCL-2 has been postulated to exert non-
apoptotic functions (Gross and Katz, 2017), although this is
controversial (Delbridge et al., 2016).
BAFF exhibits many of the biological activities that are charac-
teristic of archetypal growth factors. It activates several signaling
pathways, including those involving AKT, mechanistic target of
rapamycin (mTOR), and phosphatidylinositol 3-kinase (PI3K)
(Jacque et al., 2015; Otipoby et al., 2008; Patke et al., 2006;
Woodland et al., 2008), promotes RNA and protein synthesis,
and increases protein content and cell size (Patke et al., 2006;
Woodland et al., 2008). BAFF induces profound transcriptional
changes in B cells (Almaden et al., 2014; De Silva et al., 2016)
activating the non-canonical nuclear factor kB (NF-kB) (Claudio
et al., 2002; Kayagaki et al., 2002) and to a lesser extent the ca-
nonical NF-kB pathway (Enzler et al., 2006).
The cellular source of BAFF that sustains B cell homeostasis is
a radioresistant population of fibroblastic reticular cells (FRCs)
residing within B cell follicles (Cremasco et al., 2014; Gorelik
et al., 2003). Artificially raising BAFF levels is sufficient to enlarge
mature B cell compartments in mice (Mackay et al., 1999; Wil-
helmson et al., 2018), demonstrating that the amount of BAFF
produced under homeostatic conditions is limiting and con-
strains peripheral B cell numbers.
To investigate the role of apoptosis in mature B cell homeo-
stasis, we generated conditional knockout (cKO) mice in which
FoB and MZB cells lack both Bax and Bak1. We found that
apoptosis regulates the in vivo lifespan of FoB cells, but not
that of MZB cells, indicating that MZB cell turnover is regulated
by as-yet-unknown mechanisms. In the spleen of cKO mice,
FoB cell numbers double by 10 weeks of age. This leads to
increased intercellular competition for BAFF, compromising
the size of the MZB cell compartment, and aspects of FoB
cell biology, such as cell growth, trafficking, and competitive-
ness. Augmenting BAFF levels in cKO mice was sufficient to
restore MZB cell numbers and FoB cell growth and trafficking.
These results demonstrate that a central function of apoptosis





Deletion of Bax and Bak1 increases the lifespan of FoB
cells but not MZB cells
To examine the role of apoptosis in mature B cell homeostasis,
we generated mice in which only mature B cells lacked the
essential apoptosis effectors BAX and BAK. Mice carrying a
germline deletion of Bak1 were inter-crossed with animals
harboring a conditional allele of Bax and the CD23-cre transgene
(Tg, the latter being expressed from the transitional B cell stage
onward) (Kwon et al., 2008). We examined the efficiency of Bax
gene deletion in transitional, FoB and MZB cells purified from
cKO mice and their littermates (Figure S1A). The deleted Bax
allele could be detected in cKO cells from the T1 compartment
onward (Figure S1B). The non-excised Bax allele could be ampli-
fied in T1 and T2 cells from cKO mice, but was undetectable in
FoB and MZB cells (Figure S1B), indicating that deletion of the
conditional Bax allele was nearly complete in mature B cells.
Accordingly, FoB and MZB cells isolated from cKO mice were
resistant to pharmacological inhibition of BCL-2, BCL-XL, and
BCL-W with the BH3 mimetic drug ABT-737 (Oltersdorf et al.,
2005) (Figure S1C) and remained viable when subjected to
growth factor deprivation (GFD) (Figures S1D–S1G). These re-
sults demonstrate that the deletion of the conditional Bax allele
is complete in both FoB and MZB cells of cKO mice and that
these cells are consequently protected from apoptosis.
We next examined the role of apoptosis in the control of the
lifespan of mature B cells. To directly compare the lifespan of
WT and cKO mature B cells in the same environment, we gener-
ated mixed BM chimeras in which recipient, donor cKO (test),
and WT (competitor) cells carried distinct allelic combinations
of the Ly5 congenic marker (Figure 1A). Lineage cKO BM was
isolated from 6 individual cKO mice, and each BM suspension
was mixed with a unique suspension of lineage WT BM cells
at a 1:9 ratio and transferred into irradiated WT recipients (Fig-
ure 1A). The recipients were then administered bromodeoxyuri-
dine (BrdU) for 6 consecutive weeks—a pulse period allowing
the labeling of donor-derived mature B cells. The biological rep-
licates were analyzed at 7 different time points between 20 and
70 days of chase. Flow cytometric analysis allowed the resolu-
tion and quantification of BrdU+ cells among mature B cells of
both test and competitor origin (Figure 1B). Consistent with pre-
vious findings (Förster and Rajewsky, 1990; Rolink et al., 1998),
WT FoB cells had a lifespan of88 days (Figure 1C). The lifespan
of cKO FoB cells increased to 172 days, and their representation
within the BrdU+ FoB cell population increased accordingly over
the 7 weeks of our analysis (Figure 1D). Hence, the inhibition of
apoptosis confers a robust survival advantage to FoB cells. In
contrast, the lifespan of cKO MZB cells was identical to their
WT counterparts (Figure 1E), and their representation within
the BrdU+ compartment did not change over time (Figure 1F).
These data indicate that mature B cell subsets have a differential
requirement for apoptosis in regulating their in vivo lifespan.
Disruption of mature B cell apoptosis in vivo increases
intercellular competition
To further dissect the role of apoptosis in mature B cell homeo-
stasis, we analyzed cKO mice and Cre littermates. At 6 weeksof age, mature B cells in cKO animals were normal in terms of
numbers and cell size (Figures S2B–S2E) but expressed lower
levels of CD21 compared to control cells (Figures S2A and
S2F). Moreover, the FoB:MZB cell ratio was significantly
increased in 6-week-old cKO mice (Figure S2G). By 10 weeks
of age, CD21 expression remained low in cKO FoB cells (Fig-
ure S2H), but this did not prevent the identification of mature B
cells residing in secondary lymphoid organs and BM (Figures
2A and 2B). FoB cell numbers were doubled in the spleen of
cKO mice (Figure 2C) and trended toward an increase (without
reaching significance) in LNs (Figure 2D). Recirculating FoB
cell numbers were also doubled in the BM (Figure 2E). As previ-
ously reported (Sakai et al., 2009; Takeuchi et al., 2005), the
numbers of MZB cells were reduced in cKO mice by 10 weeks
of age (Figure 2C) and their representation within mature B cells
further decreased (Figures S2I and S2J). Of note, the size of cKO
FoB cells in 10-week-old animals was decreased compared to
controls in the spleen, LNs, and BM (Figures 2F–2H). This phe-
nomenon, called atrophy, occurs in lymphocytes deprived of
growth factors in vitro (Rathmell et al., 2000; Woodland et al.,
2008) and for as-yet-unknown reasons in Bcl-2 Tg B cells in vivo
(Sakai et al., 2009; Strasser et al., 1990, 1991b). Atrophy was not
observed in FoB cells in 6-week-old cKO mice (Figures S2D and
S2E), indicating that it is not an intrinsic property of apoptosis-
resistant B cells.
We hypothesized that atrophy may result from an increase in
competition among mature B cells due to the gradual expansion
of the FoB cell compartment over time. To test this hypothesis,
we reduced competition in 10-week-old cKO mice by depleting
B cells with specific antibodies (Figure 2I). Depletion reduced the
numbers of mature B cells in the spleen, LNs, and BM (without
reaching statistical significance) (Figure 2J), and this restored
mature B cell size in all organs (Figure 2K). This was specific to
the B cell compartment as neither the number (Figure 2L) nor
the size (Figure 2M) of CD4 T cells were affected in cKO mice.
These data demonstrate that homeostatic turnover via the
intrinsic apoptosis pathway constrains the numbers of FoB cells,
preventing competition-induced atrophy.
BAFF is the limiting factor that restricts the number and
size of mature B cells
We reasoned that reduced cell death compromises the health of
the FoB cell population by increasing competition for a B cell-
specific factor. Given its pivotal role in peripheral B cell homeo-
stasis and its ability to regulate CD21 expression (Gorelik et al.,
2004), BAFF seemed a likely candidate. Consistently, we found
that the levels of BAFF were significantly decreased in the serum
of cKO animals from 5 to 6 weeks of age (Figure 3A). Importantly,
raising BAFF availability in cKOmice via injection of recombinant
protein was sufficient to restore FoB cell size (Figures 3B and
3C). We wondered whether in mice with mature B cells resistant
to apoptosis, alleviating competition for BAFF for a sustained
period of time could further increase the size of the FoB cell pop-
ulation and restore the MZB cell compartment. To test this, we
reconstituted lethally irradiated mice expressing a BAFF Tg ex-
pressed in the radioresistant compartment with BM cells from
WT, cKO, or Cre donors (Figure 3D). Eight weeks after trans-





Figure 1. Co-deletion of Bax and Bak1 in
mature B cells extends FoB cell lifespan but
does not alter the survival of MZB cells
(A) Mixed BM marrow chimeras were generated by
transplanting a 9:1 ratio of Ly5.1+ WT lineage
competitor BM cells and Ly5.2+ cKO test cells,
respectively, into lethally irradiated Ly5.1+ Ly5.2+ re-
cipients (6 biological replicates). Chimeras were fed
BrdU for 6 weeks (Pulse). The quantification of BrdU+ B
cells was done 20, 27, 35, 43, 53, 60, and 70 days after
the end of BrdU administration (Chase).
(B) Gating strategy to quantify BrdU+ FoB and MZB
cells from WT and cKO origin.
(C) Lifespan curves of BrdU+ FoB cells. Data show
means ± SEMs (n = 6/time point). Average number of
BrdU+ cells at day 20 was set at 100%. Cell lifespan
estimates obtained from linear regression analysis: WT
cells: 88 days, cKO cells: 172 days.
(D) Representation of WT cells and cKO cells within
BrdU+ FoB cells as a function of time.
(E) Lifespan curves of BrdU+ MZB cells. Data show
means ± SEMs (n = 6/time point). Lifespan estimates:
WT cells: 92 days, cKO cells: 101 days.
(F) Representation of WT cells and cKO cells within
BrdU+ MZB cells as a function of time. Data show
means ± SDs (n = 6/time point). Data are representa-
tive of 2 independent experiments.




Figure 2. Abrogation of apoptosis in mature B cells increases FoB
cell numbers and decreases cell size by raising intercellular
competition
(A) Representative fluorescence-activated cell sorting (FACS) plots of
CD19+CD93 mature B cells in the spleen and LNs of 10-week-old cKO mice
and littermates.
(B) Representative plot of B220+CD19+ B cells in the BM. Rec, recirculating
FoB cells; Im, immature; and Prog, progenitor.
(C) Numbers of FoB and MZB cells in the spleen of cKO mice and littermates
(n = 4).
(D) Numbers of FoB cells in LNs.
(E) Numbers of B220+CD19+CD93IgM+ mature B cells in the BM.
(F–H) Relative size of mature B cells in the spleen (F), LNs (G), and BM (H).
(I) B cell depletion in cKO mice was achieved by the injection of rat antibodies
against B220 and CD19 followed by the administration of mouse anti-rat IgG
antibodies 2 days later. Control mice were injected with saline.
(J) Numbers of CD93IgM+CD23+ FoB cells in the spleen, LNs, and BM.
(K) FoB cell size in the spleen, LNs, and BM.
(L) Numbers of TCRb+CD4+ T cells.
(M) CD4+ T cell size in the spleen and LNs (n = 3).
Data are means ± SDs. Student’s t test with *p < 0.05, **p < 0.01, and ***p <
0.001. Data are representative of 2 independent experiments.
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OPEN ACCESSwas reduced inWT recipients, relative to those derived from con-
trol donors (Figures 3E and 3F). In contrast, they were similar in
BAFF Tg recipients. Hence, reducing competition for BAFF is
sufficient to restore the MZB cell population. These data indicate
that the accumulation of FoB cells in cKO mice raises the inten-
sity of competition for BAFF and thereby contracts the MZB
compartment, which, in this context, is less fit than its FoB cell
counterparts.
In contrast toMZB cells, splenic cKO FoB cells were increased
2-fold in WT recipients (Figure 3G). Their individual cell size,
however, was reduced (Figure 3H). Overexpression of BAFF
restored their size and, importantly, it increased their number
beyond those of apoptosis-sensitive controls. We then
compared the size of the FoB cells receiving different levels of
BAFF from their microenvironment (Figure 3I). FoB cells living
in a BAFF Tg host were abnormally large, whereas Bak1/Bax-
D/D FoB cells deficient for the BAFF-R (encoded by the Tnfrsf13c
gene) were highly atrophic (Figures 3I and S3). These findings
establish that BAFF exerts a central non-redundant role in regu-
lating FoB cell size in vivo and show that this activity is indepen-
dent of its anti-apoptotic function.
Collectively, data show that the abrogation of apoptosis in
mature B cells increases the size of the FoB cell compartment
and thereby raises competition for BAFF. This in turn reduces
FoB cell size and contracts the MZB cell compartment. Hence,
our results suggest that a central role of homeostatic apoptosis
in FoB cells is to restrain intercellular competition for BAFF.BAFF-dependent FoB cell growth in vitro is dependent
on gene expression
Our results suggest that BAFF-R signaling is a crucial regulator of
B cell size in vivo. We therefore aimed to better define the cellular
processes underlying FoB cell growth and the anabolic activity of
BAFF in vitro. WT cells do not lend themselves to this purpose
because of their propensity to undergo apoptosis. In contrast,
cKO FoB cells overcome this limitation, as they remain viable
in the absence of BAFF, are remarkably resistant to cytotoxicCell Reports 36, 109430, July 20, 2021 5
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Figure 3. BAFF is the limiting factor that restricts the numbers of mature B cells and the size of cKO FoB cells
(A) Serum levels of BAFF in WT, Bak1/ Baxfl/fl, and cKO mice of different ages.
(B) cKO mice were either injected with 5 mg rBAFF or saline for 2 consecutive days. FoB cell size was measured 24 h after the last injection.
(C) Relative FoB cell size in spleen and LNs (n = 3–4). The dotted lines indicate the average cell size from 2 WT controls.
(D) BM marrow chimeras were generated by transplanting either WT, Bak1/Baxfl/fl, or cKO BM donor cells (Ly5.2+) into lethally irradiated Ly5.1 recipients. The
recipients either carried a BAFF Tg expressed in radioresistant cells or were WT. Chimeras were analyzed 8 weeks post-transplant.
(E) Representative FACS plot of donor-derived mature B cells in the spleens of the chimeras.
(F and G) Numbers of splenic donor-derived MZB cells (F) and FoB cells (G).
(H) Relative size of donor-derived splenic FoB cells (n = 4).
(I) Relative size of FoB cells in the spleens of unmanipulated BAFF Tg, WT, cKO, and Bak1/Baxfl/fl Cd23-Cre Tnfrsf13c/ mice (n = 4).
Data are means ± SDs. Student’s t test with *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001.
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OPEN ACCESSagents or nutrient deprivation (Figure S4), and significantly in-
crease their size in response to treatment with BAFF (Figure 4A).
We found that the absence of either dextrose (Figure 4B) or
amino acids (aa) (Figure 4C) from the culture medium substan-
tially reduced cell size and, conversely, their presence potenti-
ated the activity of BAFF (Figures 4B and 4C). The inhibition of
oxidative phosphorylation reduced B cell size and prevented
the anabolic effect of BAFF (Figure 4D). These data indicate
that cell growth and the activity of BAFF depend upon the pres-
ence of nutrients in the environment and on energy production.
Pharmacological inhibition of translation (Figure 4E), ribosome
export (Figure 4F), or transcription (Figure 4G) decreased cell
size and prevented the effect of BAFF on cell growth. Interest-
ingly, modulating transcriptional activity in FoB cells via a titra-6 Cell Reports 36, 109430, July 20, 2021tion of actinomycin D resulted in a dose-dependent regulation
of cell size (Figure 4H). These data support the notion that tran-
scriptional activation induced by BAFF is essential for its activity
in FoB cells.
RNA sequencing (RNA-seq) analysis identifies
transcription factors (TFs) regulating BAFF-induced cell
growth
We reasoned that limiting levels of BAFF in the cKO mice may
contribute to FoB cell atrophy by reducing their transcriptional
capacity. Atrophy may result from the specific downregulation
of TFs that activate transcription in response to BAFF. Alterna-
tively, it may result from the activation of transcriptional repres-




Figure 4. BAFF-dependent FoB cell growth
in vitro is dependent on cellular processes
underpinning gene expression
(A–G) cKO FoB cells were cultured for 48 h in vitro in
the presence or absence of 25 ng/mL rBAFF. The
effect of rBAFF on cell size was assessed either in
complete DMEM (A) or in the presence or absence
of the following nutrients/drugs: 5.56 mM dextrose
(B), aa (C), 10 mMoligomycin A and 4 mMantimycin A
(D), 5 mM cyclohexamide (CHX) (E), 100 nM lep-
tomycin B (LMB) (F), or 20 nM actinomycin D (G).
(H) Titration of actinomycin D in the presence or
absence of rBAFF. Each data point represents an
individual measurement (technical replicate).
Data are means ± SDs. Student’s t test with *p <
0.05; **p < 0.01 and ***p < 0.001. Data are repre-
sentative of at least 2 independent experiments.
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OPEN ACCESSregulate BAFF-mediated cell growth, we performed RNA-seq
analysis on cKOFoB cells (which live in a BAFF-low environment)
and used Bak1/ Baxfl/fl cells (which live in a BAFF-normal envi-
ronment) as controls. Bioinformatic analysis identified 251 genes
as downregulated in cKO B cells and 195 genes upregulated
(Figure 5A). Gene set enrichment analysis revealed that tran-
scripts encoding cell-cycle regulators were less abundant in
cKO than in control FoB cells (Figure 5B). This was likely due
to the upregulation ofCdkn1a (Figures 5C and S5), as its product,
p21, stabilizes the DREAM complex, a transcriptional repressor
that inhibits the expression of cell-cycle genes (Engeland, 2018).
Of note, we found that 43% (109/251) of the genes downregu-
lated in cKO B cells are DREAM complex targets (Fischer
et al., 2016) (Figure 5D). Cdkn1a is a canonical p53 target gene
(el-Deiry et al., 1993), suggesting that the deprivation of BAFF
may trigger p53 activation. Consistent with this hypothesis,
several p53-target genes were upregulated in cKO B cells,
such as Puma and Zmat3 (Figures 5C and S5), and gene setenrichment analysis identified p53 gene
sets (Figure 5E). To investigate whether
p53 activation controls the growth of cKO
FoB cells, we generated Bak1/ Baxfl/fl
Trp53 fl/fl CD23-Cre mice. FoB cells in
these mice were found in numbers similar
to those in Bak1/ Baxfl/fl CD23-Cre con-
trols (Figure 5F), but the loss of Trp53
trended toward increasing atrophy in the
spleen and significantly aggravated it in
LNs and BM (Figure 5G). These results
demonstrate that p53 activation regulates
FoB cell size when BAFF is limiting and
represents a major brake on competition-
induced atrophy.
Among the genes downregulated in cKO
B cells, 18 encoded for TFs (Table S1), 8 of
which were targets of the DREAM complex
(Fischer et al., 2016) (Tables S1 and S2).
We focused our attention on 4 TFs based
on their potential in mediating B cell
growth. Both Myb and Spib (Figures 5Cand S6A) have been reported to play important roles in the B
cell lineage (Su et al., 1997; Thomas et al., 2005), and Relb and
Nfkb2 (Figures 5C and S6A) encode subunits of the dimer that
plays a critical role in the non-canonical NF-kB pathway (Sun,
2017). We used an in vivo assay to test whether the downregula-
tion of these TFsmay compromise BAFF-mediated cell growth in
cKO cells. BAFF Tg animals and non-Tg littermates were lethally
irradiated and reconstituted with either WT BM or BM carrying a
germline or conditional deletion of the gene encoding the TF of
interest (Figure 5H). Eight weeks after transplantation, we as-
sessed whether the loss of the TF precluded the accumulation
of mature B cells in response to transgenic BAFF. We found
that neither Myb nor Spib deficiency altered mature B cell
numbers in BAFF Tg recipients (Figures S6B–S6D). In contrast,
the loss of Relb or Nfkb2 prevented BAFF-mediated accumula-
tion of FoB and MZB cells in Tg recipients (Figures 5I–5K),
demonstrating the in vivo requirement for Relb and Nfkb2 in








Figure 5. RNA-seq analysis as a tool to
identify TFs regulating BAFF-modulated
cell growth
(A) RNA-seq analysis identifies 251 down-
regulated (including Bax) and 195 upregulated
transcripts in cKO FoB cells compared toBak1/
Baxfl/fl cells (2% and 1.5% of detected genes,
respectively).
(B) The 20 most significant gene sets identified by
Gene Ontology analysis done on differentially
expressed (DE) genes in cKO FoB cells.
(C) Volcano plot showing adjusted p value against
fold change (FC). DE transcripts with an adjusted
p < 0.05 are shown in blue.
(D) Venn diagram showing the overlap between
DREAM target genes (Fischer et al., 2016) and DE
genes in cKO B cells.
(E) Barcode enrichment plots showing enrich-
ment for p53 target genes in cKO B cells.
(F and G) Numbers (F) and relative size (G) of
Bak1/BaxD/DTpr53D/D FoB cells in the spleen,
LNs, and BM (n = 3). Data show means ± SDs.
(H) Lethally irradiated Ly5.1+ BAFF Tg and non-Tg
controls were reconstituted with either WT,
Relb/, Nfkb2/ or Spib/ BM, or Myb cKO
BM. Chimeras were analyzed 8 weeks post-
transplant.
(I and J) Numbers of donor-derived splenic FoB (I)
and MZB (J) cells.
(K) Numbers of donor-derived LN FoB cells
(n = 3–4).
Data are means ± SDs. Student’s t test with *p <
0.05 and **p < 0.01.
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OPEN ACCESScompetition for BAFF in cKO mice impairs FoB cell growth by
reducing the activity of the non-canonical NF-kB pathway at
the transcriptional level.
cKO FoB cells fail to grow in nutrient-rich environment,
display abnormal homing patterns, and exhibit a survival
defect under competitive conditions
Growth factors can regulate cell growth by modulating the ability
of cells to uptake and use nutrients (Palm and Thompson, 2017).
We therefore sought to establish whether B cells receiving vary-
ing levels of BAFF signaling in vivomay exhibit differential growth
potential in vitro. To this end, we purified LN FoB cells from WT,
Bak1/BaxD/D, andBak1/BaxD/DTnfrsf13c/mice. The three
B cell populations were mixed at an equal ratio and plated in
complete medium in the absence or presence of recombinant
BAFF (rBAFF). Each cell type carried a different allelic combina-
tion of the Ly5 congenic marker, which allowed us to track them
over time (Figure 6A). Under these conditions, WT B cells
cultured without rBAFF died over the course of 4 days (Figures
6B and 6C). At day 3, the remaining WT cells exhibited an in-
crease in size even without any addition of BAFF (Figure 6D). In
contrast, the numbers of viable Bak1/BaxD/D and Bak1/
BaxD/D Tnfrsf13c/ B cells, and their size, remained constant
throughout the experiment. As reported (Rolink et al., 2002),
the addition of BAFF to the medium slowed the death rate of
WT B cells (Figure 6C), suggesting that BAFF can restrain BAX/
BAK-mediated apoptosis. WT cells further increased in size in
response to rBAFF, whereas cKO B cells exhibited a much
less pronounced increase, albeit statistically significant (Fig-
ure 6E). These results suggest that the amount of BAFF signaling
received by B cells in vivo controls their ability to grow in nutrient-
rich environments and to respond to BAFF signals in vitro.
To determine whether deprivation of BAFF affects the surface
levels of its own receptors, nutrient receptors, adhesion mole-
cules, or chemokine receptors, we compared the surface
expression levels on FoB cells in Cre control and cKO mice.
We included BAFF Tg mice in our analysis to assess the effect
of BAFF overexpression on the expression levels of these pro-
teins. We found that cKO FoB cells express normal levels of
BAFF-R (Figure 6F). Furthermore, the levels of the alternative
BAFF receptors transmembrane activator and CAML interactorFigure 6. cKO FoB cells display defective growth in vitro, defective co
Ly5.1+ cKO (red) and Ly5.1+ Ly5.2+WT (green) and Ly5.2+Bak1/BaxD/DTnfrsf13
being submitted to growth factor deprivation for 4 days.
(A) Representation of cells of each genotype over time.
(B and C) Number of viable cells of each genotype in the presence (B) or absenc
(D and E) For each genotype, cell size was normalized for day 0 and measured a
technical replicates with means ± SDs. Data are representative of 2 independen
(F) Expression levels of BAFF-R, TACI, BCMA, adhesionmolecules, and nutrient/c
3). Data show means. Data are representative of 3 independent experiments.
(G and H) FoB cell numbers in LNs (G) and spleens (H) of 10- and 15-week-old c
(I) FoB cell numbers in LNs, blood, spleen, and BM of cKO mice injected with eit
(J) WT competitor cells and test cKO FoB cells were mixed at a 1:1 ratio, CTV la
Tnfrsf13c/ recipients or into WT recipients that had been g-irradiated with 400
(K) Representation of test and competitor FoB cells in the spleen and inguinal LN
(n=4). N.D., not determined.
(L and M) Representative CTV profile of donor FoB cells in the spleens (L) and iL
Student’s t test with *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. Data a
10 Cell Reports 36, 109430, July 20, 2021(TACI) and B cell maturation antigen (BCMA) were unchanged
and increased in cKO FoB cells, respectively (Figure 6F). These
results suggest that the inability of cKO FoB cells to increase
their size in vitro (Figures 6D and 6E) is not due to the defective
expression of receptors for BAFF. Moreover, we found that
expression levels of transferrin receptor (CD71) were normal in
cKO cells, while those for the large neutral aa transporter LAT1
were increased (Figure 6F). While the expression levels of the
chemokine receptor CXCR5were normal in cKO FoB cells, those
of CXCR4, which is crucial for the homing of recirculating FoB
cells to the BM (Nie et al., 2004), were increased (Figure 6F).
This suggests that heightened competition for BAFF may pro-
mote FoB cell accumulation in the BM of cKO mice (Figure 2E)
by upregulating CXCR4 expression. Interestingly, the expression
levels of the adhesion molecules CD44 and L-selectin (CD62L)
positively correlated with the availability of BAFF (Figure 6F).
Since L-selectin is instrumental for B cells to enter LNs via high
endothelial venules (Tang et al., 1998), low BAFF availability
may impair the entry of cKO FoB cells into LNs. Consistently,
the numbers of FoB cells in the LNs of cKO mice remained con-
stant between 10 and 15 weeks of age (Figure 6G), whereas the
numbers of spleen cells increased (Figure 6H). Strikingly, the in-
jection of rBAFF dramatically changed the distribution of FoB
cells in lymphoid organs (Figure 6I). It raised the numbers of
FoB cells in LNs and reduced those circulating in the blood or
homing within the BM. This was specific to FoB cells, as BAFF
administration did not alter the numbers or distribution of CD4
T cells (Figure S7). These findings reveal that BAFF signals
regulate FoB cell extravasation toward LNs and BM homing,
and indicate that this may be achieved through the modulation
of CD62L and CXCR4 expression, respectively.
To address whether BAFF signals control cell competitive-
ness, we examined the in vivo fate of WT and cKO FoB cells un-
der non-competitive and competitive conditions. cKO and WT
FoB cells were purified, mixed at a 1:1 ratio, and labeled with
CellTrace Violet (CTV). These cell mixtures were then adoptively
transferred into recipients with either reduced or normal FoB cell
compartments to assess their survival when facing endogenous
competition of various intensity. Rag1/, irradiated WT, and
Tnfrsf13c/ mice provided a non-competitive environment
while non-irradiated WT recipients offered a competitivempetitiveness, and altered trafficking in vivo
c/ (orange) B cells were isolated from LNs andmixed in equal numbers before
e (C) of 25 ng/mL rBAFF.
fter 3 days of culture in the absence (D) or presence (E) of rBAFF. Data show
t experiments.
hemokine receptors on FoB cells in BAFF Tg,Bak1/Baxfl/fl, and cKOmice (n =
KO mice and littermates (n = 3–4). Data show means ± SDs.
her PBS or BAFF (as described for Figure 3B). Data show means ± SDs.
beled, and adoptively transferred either into unmanipulated WT, Rag1/, or
Rad (4 recipients/group).
s (iLNs) of recipients 5, 18, or 40 days after transfer. Data show means ± SDs,
Ns (M) of recipients.
re representative of 2 independent experiments.
Figure 7. Abrogation of apoptosis in mature B cells perturbs TI-antibody responses
cKO and Bak1/Baxfl/fl littermates were immunized intraperitoneally (i.p.) with NP-Ficoll and analyzed 5 and 11 days later.
(A) Numbers of splenic B220+CD138+ plasmablasts determined by flow cytometry 5 and 11 days post-immunization.
(B and C) ELISpot analysis of NP+IgM+ (B) and NP+IgG3+ (C) splenic antibody-secreting cells 5 and 11 days post-immunization.
(D and E) ELISA analysis of NP-specific IgM (D) and IgG3 (E) serum antibody 5 days post-immunization. Data show means ± SEMs (n = 6). Mann-Whitney
nonparametric, 2-tailed test with *p < 0.05 and **p < 0.01. Data are representative of 2 independent experiments.
(F) Expression levels of BAFF-R and TACI onMZB cells in BAFF Tg,Bak1/Baxfl/fl, and cKOmice (n = 3). Student’s t test with *p < 0.05 and ***p < 0.001. Data are
representative of 3 independent experiments.
(G and H) ELISA analysis of NP-specific IgM (G) and IgG3 (H) serum antibody 11 days post-immunization (n = 6). Data show means ± SEMs. Mann-Whitney
nonparametric, 2-tailed test with *p < 0.05 and **p < 0.01.
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OPEN ACCESSenvironment (Figure 6J). Five days after transfusion, cKO FoB
cells were present at the same frequency as WT FoB cells in
the spleen and inguinal LNs (Figure 6K), and neither cell type
had undergone cell division (Figures 6L and 6M). After 40 days
in a non-competitive environment, cKO FoB cells were overrep-
resented compared to WT control FoB cells (Figure 6K). As ex-
pected (Cabatingan et al., 2002), their CTV profile showed that
these cKO FoB cells were in most cases the product of several
rounds of division (Figures 6L and 6M). This demonstrates that
cKO FoB cells can survive for extended periods of time under
non-competitive conditions and that resistance to apoptosis
confers a substantial survival advantage over their co-trans-
planted WT counterparts during lymphopenia-induced prolifera-
tion. In striking contrast, 18 days after transfer into unmanipu-
lated WT recipients (competitive condition), cKO FoB cells
were completely absent, whereas their WT competitors were still
present in the recipients’ spleens and LNs without having under-
gone proliferation (Figures 6K–6M). These results demonstrate
that cKO FoB cells have a profound survival defect under normal
competitive conditions.
These findings indicate that by restraining competition for
BAFF, apoptosis modulates fundamental aspects of FoB cellphysiology, such as cell growth in response to nutrients and
BAFF, migration, and competitiveness.
Thymus-independent (TI) antibody responses are
perturbed in cKO animals
We next investigated whether the disruption of apoptosis may
compromise mature B cell function. We immunized cKO mice
and littermate controls with 4-hydroxy-3-nitrophenylacetic
(NP)-Ficoll to elicit a TI antibody response. After 5 days, the total
numbers of plasmablasts were increased in the spleen (Fig-
ure 7A), suggesting that the disruption of apoptosis does not
hinder B cell activation. However, while the numbers of NP-spe-
cific cells secreting IgMwere normal at this timepoint (Figure 7B),
the numbers of cells producing IgG3 were lower than in control
mice (Figure 7C). These results were mirrored in the serum of
cKOmice, where titers of NP-specific IgM and IgG3were normal
and reduced, respectively (Figure 7D and 7E), suggesting that Ig
class switch recombination (CSR) was delayed or impaired in
cKOmice. Because BAFF can support CSR by signaling through
both BAFF-R and TACI (Castigli et al., 2005), we investigated the
levels of these receptors by flow cytometry. They were normal in
cKO FoB cells (Figure 6F) and BAFF-R levels were increased inCell Reports 36, 109430, July 20, 2021 11
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These results show that the disruption of apoptosis in mature B
cells compromises the generation of antigen-specific IgG3 anti-
bodies in the early phase of TI humoral immune response,
possibly by putting a brake on BAFF/BAFF-R signaling-sup-
ported Ig CSR.
We next assessed whether abrogation of apoptosis only de-
layed the induction of the humoral immune response against
NP-Ficoll or whether it continued to undermine it/inhibit the
response over time. To this end, we analyzed cKO and control
mice 11 days after immunization. While the numbers of plasma-
blasts in control mice did not significantly change between 5 and
11 days post-immunization, those in cKO mice increased during
this time frame (Figure 7A). Furthermore, 11 days after immuniza-
tion, the numbers of NP-specific cells secreting IgM and IgG3 in
cKOmice both exceeded those of control littermates (Figures 7B
and 7C) and the antibody titers in the serum were accordingly
increased (Figures 7G and 7H). These results suggest that in
WT mice, apoptosis limits the production of antigen-specific an-
tibodies during the later phase of TI humoral responses by con-
straining the numbers of antibody-secreting cells.
These findings suggest that abrogation of apoptosis substan-
tially perturbs TI humoral responses. Five days after antigenic
challenge, it limits the generation of antigen-specific IgG3+
plasma cells and serum IgG3+ antibodies, whereas in contrast,
11 days after immunization, it increases the amplitude of the an-
tigen-specific humoral response.
DISCUSSION
We found that under homeostatic conditions, the turnover of
distinct subsets of mature B cells is differentially regulated by
apoptosis. FoB cells reaching the end of their lifespan die via
apoptosis, but this is not the case forMZB cells.We demonstrate
that the disruption of apoptosis leads to the accumulation of FoB
cells in lymphoid organs, which in turn increases intercellular
competition for BAFF. This has dramatic consequences for all
mature B cell subsets, contracting the MZB cell compartment
and altering fundamental aspects of FoB cell physiology. Hence,
our results support a model whereby competition for cell-type-
specific growth factors produced in limiting quantities underpins
tissue homeostasis (Raff, 1992) and illustrate how changes in
competition intensity affect lymphoid homeostasis (Freitas and
Rocha, 2000).
The apoptosis pathway is operative in MZB cells as seen by
the fact that WT cells undergo apoptosis in response to ABT-
737 and growth factor deprivation in vitro and that inducible
Mcl-1 deletion depletes MZB cells (Vikström et al., 2016).
However, our BrdU labeling experiments demonstrate that
apoptosis does not constrain the MZB cell lifespan in normal
mice in vivo. Thus, apoptosis is dispensable for MZB cell ho-
meostasis, an emerging theme in studies of other mammalian
tissues (Ke et al., 2018; Lindsten et al., 2000; Lindsten and
Thompson, 2006). It is increasingly evident that the role played
by apoptosis in the homeostatic turnover of a given cell popu-
lation cannot be inferred from the apoptotic death of these cells
in vitro, but requires the evaluation of their lifespan at steady
state in vivo.12 Cell Reports 36, 109430, July 20, 2021Our data imply that MZB cell turnover is controlled by mecha-
nisms other than the intrinsic apoptotic pathway. Necroptosis
and death receptor-induced apoptosis are unlikely to be impli-
cated because B lymphoid homeostasis is normal in mice in
which these pathways are abrogated (Alvarez-Diaz et al.,
2016). While MZB cells can undergo ferroptosis in response to
lipid peroxidation (Muri et al., 2019), whether it is engaged under
homeostatic conditions is unknown. Conceivably, the turnover of
MZB cells may occur through the concerted activation of multi-
ple genetically programmed cell death pathways (Bedoui et al.,
2020). It could also be affected independent of genetically pro-
grammed pathways, perhaps akin to the disposal of aged red
blood cells by macrophages (de Back et al., 2014).
While BAFF-R signaling is instrumental for the survival of FoB
and MZB cells in vivo (Rauch et al., 2009), it likely controls the
viability of these cells through different pathways. Resistance
to apoptosis allows the progressive enlargement of the FoB
cell population, despite low BAFF availability in cKO mice,
whereas in contrast, it fails to protect the MZB cell population,
which contracts under the same conditions. The number of
cKO FoB cells that develop in BAFF Tg recipients exceeds those
of apoptosis-sensitive cells, yet the same is not true for cKO
MZB cells. Furthermore, abrogation of apoptosis in vivo can
partially substitute for BAFF-R activity in FoB cells, but fails to
do so in MZB cells (Tardivel et al., 2004). These findings indicate
that BAFF-R signaling promotes survival in FoB cells by antago-
nizing apoptosis, while in MZB cells this is achieved by a non-
apoptotic, as-yet-unknown pathway. They further suggest that
resistance to apoptosis renders FoB cells but not MZB cells
less dependent on BAFF signals for survival, which may explain
why it extends the in vivo lifespan of the former but not of the
latter.
In FoB cells, BAFF is thought to block apoptosis bymodulating
the expression of key apoptotic regulators (Craxton et al., 2005;
Do et al., 2000; Hsu et al., 2002; Jacque et al., 2015; Woodland
et al., 2008).We show that BAFF deprivation in vivo activates p53
and triggers the upregulation of Puma, a major pro-apoptotic
p53 target (Nakano and Vousden, 2001; Villunger et al., 2003).
Hence, our results suggest that WT FoB cells that have failed
to receive BAFF signals beyond a critical threshold may undergo
apoptosis as a result of p53 activation.
In FoB cells that are normally sensitive to apoptosis, interfer-
ence with BAFF-R signaling rapidly triggers cell death, which
precludes a comprehensive understanding of the role of BAFF
in the physiology of these cells. The disruption of apoptosis in
cKO FoB cells overcomes this limitation and offers an opportu-
nity to identify novel facets of FoB cell biology that are regulated
by BAFF.
We show that the abrogation of apoptosis in mature B cells
leads to the enlargement of the FoB cell compartment in the
spleen and BM, thereby raising the intercellular competition for
BAFF, which in turn compromises the growth of FoB cells.
Decreasing competition for BAFF is sufficient to restore FoB cell
size and to further increase their numbers. This demonstrates
that the limited BAFF availability (Mackay et al., 1999; Wilhelmson
et al., 2018) enforces competition amongmature B cells and natu-
rally constrains FoB cell size and number. Our results further sug-
gest that BAFF-R signaling may further affect FoB cell growth by
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ronments. While our results are consistent with the role of growth
factors in regulating nutrient uptake (Lum et al., 2005; Palm and
Thompson, 2017), we did not find evidence that BAFF deprivation
decreased the expression of nutrient receptors as observed
in vitro for other growth factors (Edinger and Thompson, 2002;
Rathmell et al., 2003). We found that cKO FoB cells are prema-
turely cleared under normal competitive conditions in vivo despite
their profound resistance to apoptosis. Cells with decreased gene
expression are known to be efficiently eliminated at the expense
of normal competitors (Claverı́a et al., 2013; Morata and Ripoll,
1975; Oliver et al., 2004). By regulating gene expression and
cell growth, BAFF signals may therefore regulate B cell competi-
tiveness. Hence, autocrine provision of BAFF in malignancies
could undermine the tumor suppressor function that is normally
exerted by cell competition in vivo (Martins et al., 2014). The un-
derstanding that BAFF availability affects cell growth and
competitiveness in vivo may be relevant for elucidating the rela-
tionship between BAFF overexpression and B cell malignancies
in humans (He et al., 2004; Kern et al., 2004; Moreaux et al.,
2004) and mice (Batten et al., 2004).
Our findings reveal an underappreciated role for BAFF in regu-
lating FoB cell homing and trafficking. We show that the admin-
istration of rBAFF is sufficient to restore the ability of blood-borne
FoB cells to enter peripheral LNs in cKO mice. Coincidently, the
levels of L-selectin, an adhesionmolecule essential for LN extrav-
asation (Tang et al., 1998) reflect BAFF availability. In contrast,
CXCR4 expression on FoB cells is inversely correlated with
BAFF availability, which may drive the accumulation of cKO cells
in the BM (Brenner et al., 2004). Raising BAFF levels in cKOmice
releases FoB cells from this niche. Collectively, our findings
show that BAFF-R signaling controls FoB cell migration and sug-
gest that it may do so by modulating the expression of critical
regulators of cell trafficking.
We show that transcription is necessary for BAFF-driven cell
growth in vitro, suggesting that BAFF-induced transcription is
instrumental to sustain B cell growth. Because cKO FoB cells
survive under reduced BAFF availability, these cells can be
used as an in vivo platform to identify transcriptional programs
that regulate BAFF-driven cell growth. Our analysis identified
that transcripts encoding Nfkb2 and Relb, the two subunits of
the critical effector of the non-canonical NF-kB pathway, were
reduced in cKO B cells, suggesting that they may act down-
stream of BAFF-R. Constitutive NF-kB activation restores the
survival and numbers of mature B cells in BAFF and BAFFR
KO mice (Gardam et al., 2008; Gardam et al., 2011; Sasaki
et al., 2006). This indicates that the NF-kB pathway is the
main, if not the sole, transcriptional program that is critical for
the cellular responses to BAFF. Accordingly, our BM chimera ex-
periments demonstrate that both Nfkb2 and Relb are indispens-
able for the responsiveness ofmature B cells to BAFF. It is known
that BAFF supportsNfkb2 transcription (De Silva et al., 2016) and
that Relb promotes its own transcription in a feedforward pro-
cess (Bren et al., 2001). Hence, the decreased availability of
BAFF may directly cause the combined downregulation of
Nfkb2 and Relb in cKO FoB cells. This may in turn severely
compromise the transcription of NF-kB target genes as the co-
deletion of Nfkb2 and Relb is more detrimental to mature B cellsthan the loss of either alone (De Silva et al., 2016). Hence, our
findings support the notion that BAFF deprivation causes FoB
cell atrophy by dampening the non-canonical NF-kB pathway
at the transcriptional level.
Our results further suggest that BAFF deprivation causes p53
activation. Supporting the idea that the effector mechanisms of
p53 are context dependent (Kastenhuber and Lowe, 2017), we
show that p53 plays a non-redundant role in cKO FoB cell growth
and restrains atrophy. Whether this protective response de-
pends on macro-autophagy (Feng et al., 2005; Tasdemir et al.,
2008) or whether it drives other p53-driven processes remains
to be established.
In conclusion, we show that apoptosis regulates the FoB cell
lifespan, but it does not control the lifespan of MZB cells. We
further demonstrate that the blockade of apoptosis in mature B
cells increases FoB cell numbers and thereby raises intercellular
competition for BAFF. This in turn reduces the size of the MZB
cell compartment, perturbs TI-antibody responses, and pro-
foundly affects the physiology of FoB cells by altering their
migration and by undermining their size, as well as their ability
to grow and to compete. Hence, our results suggest that the
essential role of apoptosis is to limit the stringency of intercellular
competition for BAFF among mature B cells.
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zler, A.K., Pan-Hammarström, Q., Hammarström, L., Rakhmanov, M., et al.
(2009). B-cell activating factor receptor deficiency is associated with an
adult-onset antibody deficiency syndrome in humans. Proc. Natl. Acad. Sci.
USA 106, 13945–13950.
Wei, M.C., Zong,W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross,
A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., and Korsmeyer, S.J.
(2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science 292, 727–730.
Weih, F., Carrasco, D., Durham, S.K., Barton, D.S., Rizzo, C.A., Ryseck, R.P.,
Lira, S.A., and Bravo, R. (1995). Multiorgan inflammation and hematopoietic
abnormalities in mice with a targeted disruption of RelB, a member of the
NF-kappa B/Rel family. Cell 80, 331–340.Wilhelmson, A.S., Lantero Rodriguez, M., Stubelius, A., Fogelstrand, P., Jo-
hansson, I., Buechler, M.B., Lianoglou, S., Kapoor, V.N., Johansson, M.E.,
Fagman, J.B., et al. (2018). Testosterone is an endogenous regulator of
BAFF and splenic B cell number. Nat. Commun. 9, 2067.
Woodland, R.T., Fox, C.J., Schmidt, M.R., Hammerman, P.S., Opferman, J.T.,
Korsmeyer, S.J., Hilbert, D.M., and Thompson, C.B. (2008). Multiple signaling
pathways promote B lymphocyte stimulator dependent B-cell growth and sur-
vival. Blood 111, 750–760.
Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M.L., Visvader, J.E., and Smyth,
G.K. (2010). ROAST: rotation gene set tests for complex microarray experi-
ments. Bioinformatics 26, 2176–2182.
Youle, R.J., and Strasser, A. (2008). The BCL-2 protein family: opposing activ-
ities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59.
Young, M.D., Wakefield, M.J., Smyth, G.K., and Oshlack, A. (2010). Gene
ontology analysis for RNA-seq: accounting for selection bias. Genome Biol.
11, R14.Cell Reports 36, 109430, July 20, 2021 17
Article
ll





PE anti-mouse BAFF-R (7H22-E16) Antibody Biolegend Cat#134103; RRID:AB_1626160
PE anti-mouse CD4 (GK1.5) Antibody Biolegend Cat#100408; RRID:AB_312693
PE/Cy7 anti-mouse CD8a (53-6.7) Antibody Biolegend Cat#100722; RRID:AB_312761
FITC anti-mouse CD21(7E9) Antibody Biolegend Cat#123408; RRID:AB_940403
PE anti-mouse CD23 (B3B4) Antibody Biolegend Cat#101608; RRID:AB_312833
FITC anti-mouse/human CD44 (IM7) Antibody Biolegend Cat#103006; RRID:AB_312957
APC/Cy7 anti-mouse CD45.1 (A20) Antibody Biolegend Cat#110716; RRID:AB_313505
Brilliant Violet 785 anti-mouse CD45.2 (104) Antibody Biolegend Cat#109839, RRID:AB_2562604
APC anti-mouse CD62L (MEL-14) Antibody Biolegend Cat#104412; RRID:AB_313099
PE/Cy7 anti-mouse CD71(RI7217) Antibody Biolegend Cat#113812, RRID:AB_2203382
PE anti-mouse CD98 (4F2) Antibody Biolegend Cat#128207; RRID:AB_1186107
Brilliant Violet 421 anti-mouse
CXCR5 (L138D7) Antibody
Biolegend Cat#145511; RRID:AB_2562127
PE anti-mouse TACI (8F10) Antibody Biolegend Cat#133403; RRID:AB_2240584
APC anti-mouse TCRb chain (H57-597) Antibody Biolegend Cat#109211; RRID:AB_313434
PE-Cyanine7 CD19 Antibody (1D3) eBioscience Cat#25-0193-82; RRID:AB_657663
Biotin Anti-CD19 Antibody (1D3) BD Biosciences Cat# 553784; RRID:AB_395048
FITC Anti-IgM Antibody (II/41) BD Biosciences Cat# 553437; RRID:AB_394857
APC anti-mouse CD93 Antibody (AA4.1) BioLegend Cat# 136510; RRID:AB_2275868
APC anti CXCR4 Antibody (2B11) Thermo Fisher Scientific Cat# 17-9991-80; RRID:AB_10670877
eFluor 450 anti CD93 Antibody (AA4.1) Thermo Fisher Scientific Cat# 48-5892-80; RRID:AB_2574084
FITC anti-BCMA Antibody (161616) R and D Systems Cat# FAB593F; RRID:AB_2256028
eFluor 450 Streptavidin Thermo Fisher Scientific Cat# 48-4317-82; RRID:AB_10359737
Brilliant Violet 785 Streptavidin BioLegend Cat#405249
Alexa Fluor 700 Streptavidin Thermo Fisher Scientific Cat#S21383
Biotin anti-mouse/human
CD45R/B220 antibody (RA3-6B2)
Biolegend Cat# 103204; RRID:AB_312989
Biotin anti-mouse CD3 antibody (17.A2) Biolegend Cat# 100244; RRID:AB_2563947
Biotin anti-mouse CD4 antibody (GK1.5) Biolegend Cat# 100404; RRID:AB_312689
Biotin anti-mouse CD8a antibody (53.6.7) Biolegend Cat# 100704; RRID:AB_312743
Biotin anti-mouse F4/80 antibody (BM8) BioLegend Cat# 123106; RRID:AB_893501
Biotin anti-mouse Gr-1 antibody (RB6-8C5) BioLegend Cat# 108404; RRID:AB_313369
Biotin anti-mouse NK-1.1 antibody (PK136) BioLegend Cat# 108704; RRID:AB_313391
APC anti-mouse TER-119 antibody (TER-119) BioLegend Cat# 116212; RRID:AB_313713
APC anti-mouse CD117 antibody (2B8) BioLegend Cat# 105812; RRID:AB_313221
PE/Cy7 anti-mouse Sca-1 antibody (D7) BioLegend Cat# 108114; RRID:AB_493596
Pacific Blue anti-BrdU Antibody (MoBU-1) Thermo Fisher Scientific Cat# B35129; RRID:AB_2536433
Goat anti-mouse IgG3 HRP (polyclonal) Southern Biotech Cat # 1100-05; RRID: AB_2794573
Goat anti-mouse IgM HRP (polyclonal) Southern Biotech Cat # 1020-05; RRID: AB_2794201
Purified anti-B220 antibody (clone RA3-6B2) WEHI antibody facility N/A
Purified anti-CD19 antibody (clone 1D3) WEHI antibody facility N/A
(Continued on next page)
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Purified anti-rat IgG antibody (clone TIB216) WEHI antibody facility N/A
FITC Anti-IgM Antibody (II/41) BD Biosciences Cat#550676; RRID:AB_398464
Purified Anti-IgM Antibody (II-41) BD Biosciences Cat#553435; RRID:AB_394855
Biotin Anti-IgD Antibody (11-26) Origene Cat#AM08012BT-N; RRID:AB_1873226
Purified Anti-CD21 Antibody (SC0681) Invitrogen Cat#MA5-32227; RRID:AB_2809513
Donkey anti-Rabbit IgG Alexa Fluor Plus 647 Thermo Fisher Scientific Cat# A32795; RRID:AB_2762835
Streptavidin, Alexa Fluor 568 Thermo Fisher Scientific Cat# S-11226; RRID:AB_2315774
Donkey anti-Rat IgG Alexa Fluor 488 Thermo Fisher Scientific Cat# A-21208; RRID:AB_2535794
Biological samples
Rat serum Sigma R9759
Chemicals, peptides, and recombinant proteins
5-Bromo-20-deoxyuridine Sigma Cat#B5002
recombinant human BAFF PeproTech Cat#310-13
Paraformaldehyde Sigma Cat#158127
TWEEN 20 Sigma Cat#P1379
RNase-Free DNase Promega Cat#M6101





L-Tyrosine disodium salt dihydrate Sigma Cat#RES3156T-A701X
L-Histidine monohydrochloride monohydrate Sigma Cat#H8125
L-Isoleucine Sigma Cat#I2752
L-Leucine Sigma Cat#L8000








L-Cystine dihydrochloride Sigma Cat#C6727
D-Glucose Sigma Cat#G7021
Cyclohexamide Sigma Cat#C7698
Leptomycin B Sigma Cat#L2913
Antimycin A Sigma Cat#A8674
Oligomycin Selleck Cat#S1478
Actinomycin D Sigma Cat#A9415
Cell Trace Violet Invitrogen Cat#C34557
Perm/Wash Buffer BD Biosciences Cat#554723
Cytofix/Cytoperm buffer BD Biosciences Cat#554722
OPD-substrate solution Sigma Cat#P9187
NBT/BCIP Stock Solution Sigma Cat#11681451001
Bovine Serum Albumine (cell culture) PAA laboratories Cat#K51-001
Propidium iodide Sigma Cat#P4864
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Critical commercial assays
QIAamp DNA Blood Mini Kit QIAGEN Cat#51104
RNeasy extraction Mini kit QIAGEN Cat#74104
DreamTaq Green PCR Master Mix Thermo Fisher Scentific Cat#K1081
Deposited data
RNA-sequencing data This paper GSE158475
Experimental models: organisms/strains
Mouse: Bak1 KO Lindsten et al., 2000 RRID:MGI:2656013
Mouse: BAFF Tg Mackay et al., 1999 MGI:2386944
Mouse: Tnfrsf13c KO Sasaki et al., 2004 RRID:MGI:3716689
Mouse: Rag1 KO Spanopoulou et al., 1994 MGI:2448994
Mouse: Nfkb2 KO Franzoso et al., 1998 MGI:2179705
Mouse: Relb KO Weih et al., 1995 MGI:2179545
Mouse: Spib KO Su et al., 1997 MGI:2448991
Mouse: floxed Bax Takeuchi et al., 2005 MGI:3589203
Mouse: floxed Myb Emambokus et al., 2003 MGI:3037362
Mouse: floxed Tpr53 Jonkers et al., 2001 MGI:2156651
Mouse: CD23-Cre Tg Kwon et al., 2008 MGI:3803652; RRID:IMSR_JAX:028197
Oligonucleotides
FWD-Bxfl Integrated DNA Technologies ACTAGGCCCGGTCCAAGAAC
RVS-Bxfl Integrated DNA Technologies GAATGCCAAAAGCAAACAGACC
RVS-del Integrated DNA Technologies GGCCCCCAAAACTCAGCTAC
Software and algorithms
Flowjo (Treestar) FlowJo, LLC https://www.flowjo.com/
Prism, version 8 Graph Pad https://www.graphpad.com/
scientific-software/prism/
ImageJ National Institutes of Health (NIH) https://imagej.nih.gov/ij/
Other
Anti-Biotin MicroBeads Miltenyi Biotec Inc. Cat#130-090-485
LS Columns Miltenyi Biotec Inc. Cat#130-042-401
CaliBRITE APC Beads BD Biosciences Cat#340487
Microtainer tubes containing EDTA Sarstedt Cat#20.1341.100
Ficoll-Paque PLUS Cytiva Cat#17-1440-02
DMEM GIBCO Cat#11885084
DMEM No Glucose GIBCO Cat#11966025
DMEM, high glucose GIBCO Cat#10313021





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stéphane
Chappaz (stephane.chappaz@monash.edu).
Materials availability
The mouse lines generated in this study may be obtained (pending continued availability) from the lead contact with a completed
materials transfer agreement.e3 Cell Reports 36, 109430, July 20, 2021
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OPEN ACCESSData and code availability
d RNA-seq data have been deposited at GEO and are publicly available as of the date of publication via accession number GEO:
GSE158475.
d All methods used to analyze these data are publicly available in the open-source R packages referred to the methods.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Animals were bred andmaintained at TheWalter and Eliza Hall Institute ofMedical Research Animal Facility and atMonash University
in specific pathogen-free facilities. Experiments were conducted as sex unbiased, with mice randomly assigned to experimental
groups. All mice used for in vivo and in vitro experiments were between 10 and 12 weeks of age unless specified otherwise. Mice
carrying the CD23-Cre Tg (Kwon et al., 2008), the BAFF Tg (Mackay et al., 1999), the germline deletion of Bak1 (Lindsten et al.,
2000), Tnfrsf13c (Sasaki et al., 2004), Rag1 (Spanopoulou et al., 1994), Nfkb2 (Franzoso et al., 1998), Relb (Weih et al., 1995),
Spib (Su et al., 1997) or the floxed alleles of Bax (Takeuchi et al., 2005), Myb (Emambokus et al., 2003) and Trp53 (Jonkers et al.,
2001) have been previously described. All lines were maintained on a C57BL/6 genetic background.
Animal experiments
All animal experiments complied with the regulatory standards of, and were approved by, the Animal Ethics Committees of The Wal-
ter and Eliza Hall Institute (WEHI) and Monash University. For quantification of spleen and LN lymphocyte populations, tissues were
homogenized between two glass slides and cells enumerated by flow cytometry with CaliBRITE beads (BDBiosciences). For analysis
of LNs in cKO mice and chimeric mice, inguinal, brachial and axillary LNs were pooled together. Automated blood cell counts were
performed on blood collected from the retro-orbital plexus into Microtainer tubes containing EDTA (Sarstedt) using an Advia 2120
hematological analyzer (Siemens). For BM chimera experiments, Ly5.1+ recipients were lethally irradiated (2x 5.5 Gy) before being
reconstituted with 5x106 Ly5.2+ BM donor cells. Chimeras were analyzed 8 weeks after transplantation. For antibody mediated
cell depletion experiments, antibodies were generated in the WEHI antibody facility. Bak1/Baxfl/fl CD23-Cre mice received i.v. in-
jections of 150 mg of monoclonal antibodies against B220 (clone RA3-6B2) and CD19 (clone 1D3) on day 0 followed by i.v. injection of
150 mg monoclonal anti-rat IgG antibody (clone TIB216) on day 2. Lymphoid compartments were analyzed at day 4 using antibodies
against IgM (clone II/41) and CD23 (clone B3B4) for identifying Fo B cells. For experiments with recombinant cytokine, 5 mg of human
BAFF (PreproTech) or saline were injected i.v. into Bak1/ Baxfl/fl CD23-Cre mice for two consecutive days before analysis. For
adoptive transfer experiments, peripheral LNs and spleens from WT and Bak1/ Baxfl/fl CD23-Cre donor animals were first stained
with biotinylated monoclonal antibodies against CD19 (clone 1D3) and then incubated with magnetic anti-Biotin beads (Miltenyi
Biotech). CD19+ B cells were then positively selected onMACS columns (Miltenyi Biotech), enumerated by flow cytometry andmixed
at 1:1 ratio. These cell suspensions were CTV-labeled as previously described (Quah and Parish, 2012). Briefly, cells were resus-
pended in RPMI medium supplemented with 10% fetal calf serum (SIGMA) at a concentration of 100x106 cells per mL and stained
with 80 mM CTV (Invitrogen) for 5 min at room temperature. Cells were then washed 3 times and approximately 5x106 CTV-labeled
cells were injected i.v. per recipient. The cells of different origin (test, competitor and recipient) all carried unique combinations of the
congenic Ly5.1 and Ly5.2 markers. At the indicated time points, spleen and inguinal LNs of the recipients were analyzed by flow cy-
tometry. For immunization, NP55-Ficoll was diluted in sterile PBS to a final concentration of 40 mg/100 mL and administered to each
mouse i.p.. Mice were analyzed 5 days post-immunisation.
METHOD DETAILS
Flow cytometry
Flow cytometric acquisition of data was performedwith BDBiosciences LSR, FACSCanto II, Fortessa, FACSVerse and FACSCalibur
analyzers. Acquisition for Fo B cell phenotyping was done on an Aurora (Cytek) machine with autofluorescence removal. Flow Jo
software was used for data analysis. Organ cellularity and in vitro cell counts were determined by flow cytometry by adding a known
number of APC-labeled CaliBRITE beads (BD Biosciences) to samples. Blood-borne lymphocytes were purified with Ficoll-Paque
PLUS (Cytiva). Relative cell size for ex vivo and in vitro experiments was obtained from the ratio between forward light scatter of viable
cells and CaliBRITE beads. Antibodies for flow cytometry and cell sorting were labeled with FITC, PE, PE-Cy7, APC, Alexa Fluor 700,
APC-Cy7, Pacific Blue, eFluor450 and biotin. Antibodies against B220 (RA3-6B2), BAFFR (7H22-E16), CD4 (GK1.5), CD8a (53.6.7),
CD21 (7E9), CD23 (B3B4), CD44 (IM7) CD45.1 (A20), CD45.2 (104), CD62L (MEL14), CD71 (RI7217), CD93 (AA4.1) CD98 (RL388),
CD117 (2B8), CXCR5 (L138D7), Sca1 (D7), TACI (8F10) and TCRb (H57-597) were purchased from Biolegend. Antibodies against
CD19 (1D3) and IgM (II/41) were purchased from BD Biosciences. Antibodies against CD93 (AA4.1) and CXCR4 (2B11) were pur-
chased from Thermo Fisher Scientific. The antibody against BCMA (161616) was purchased from R&D systems. As secondary re-
agents, Streptavidin-eFluor450 (Thermo Fisher Scientific), Streptavidin-BV785 (Biolegend), and Streptavidin-Alexa700 (MolecularCell Reports 36, 109430, July 20, 2021 e4
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sorting was done on Influx and FACS Aria (BD Biosciences) cell sorters with > 99.5% purity.
BrdU labeling in mixed BM chimeric mice
BM cells from 6 individual Ly5.2+ Bak1/ Baxfl/fl CD23-Cre (test) donors and from several Ly5.1+ WT (competitor) donors were suc-
cessively stained with biotin-labeled antibodies against lineage markers (B220 (RA3-6B2), CD3 (17.A2), CD4 (GK1.5), CD8a (53.6.7),
F4/80 (BM8), Gr1 (RB6-8C5), NK1.1 (PK136), Ter119 (TER-119) purchased from Biolegend and CD19 (1D3) purchased from BD Bio-
sciences) and then incubated with magnetic anti-Biotin beads (Miltenyi Biotech). Lineage- progenitors were then negatively selected
onMACS columns and viable cells were enumerated by flow cytometry. Each of the 6 progenitor suspensions from a Ly5.2+ Bak1/
Baxfl/fl CD23-Cre donor was mixed at 1:9 ratio with the competitor Ly5.1+ WT cell suspension. For each mix, the 1 to 9 ratio was
confirmed by flow cytometry in lineage- c-Kit+Sca1+ cells. Each of these 6 mixed cell suspensions was then used to reconstitute
7 Ly5.1+ Ly5.2+ recipient mice that had previously been irradiated with 900 rad. The following day, the recipients were injected
with 40 mg/kg of BrdU (Sigma) and received BrdU (0.8 mg/L) in the drinking water for 6 consecutive weeks. During the chase period,
six recipients that had received test cells of distinct origin were analyzed at the indicated time point. Splenocyte numbers were
counted by flow cytometry and stained with antibodies against CD19, CD21, CD23, CD45.1, CD45.2 and CD93. Theywere then fixed
overnight in Cytofix/Cytoperm buffer (BD Biosciences) at 4C, washed once in Perm/Wash buffer (BD Biosciences) and resuspended
in 1%PFA (Sigma) 0.5%Tween-20 (Sigma) (v/v) in PBS for 30min at room temperature. After a single wash in Perm/Wash buffer, cells
were fixed a second time in Fix/Perm buffer on ice for 15min, washed twice in Perm/Wash buffer before being resuspended in 0.15M
NaCl and 4.2 mMMgCl2 with 50 U of DNase (Promega). DNase treatment was performed at 37
C for 30 min. Cells were then washed
twice in Perm/Wash buffer and stained with an antibody against BrdU (clone MoBU-1, Life Technologies) for 30 min on ice. After 2
washes in Perm/Wash buffer, quantification of BrdU+ cells of test and competitor origin was done by flow cytometry.
In vitro assays
For experiments probing cell size regulation, Fo B cells were isolated from peripheral LNs. LN cells were stained with a biotinylated
antibody against CD19 and then incubated with anti-Biotin beads (Miltenyi Biotech). Fo B cells were positively selected with LS col-
umns (Miltenyi Biotech) and their purity was routinely > 98%. cKO Fo B cells were plated in 96 well plate U bottom plates (Falcon) in
either complete DMEM (GIBCO), sugar-free DMEM (GIBCO) or aa free DMEM (US Biological life sciences) and medium were sup-
plemented with 2%BSA (PAA laboratories) at cell density of 25x103-40x103 cells/well. Dextrose, CHX, LMB, Oligomycin, Antimycin,
ActD and all aa (L-Arg-HCl, Glycine, L-serine, L-Tyrosine disodium salt dehydrate, L-Histidine monohydrochloride monohydrate, L-
Isoleucine, L-Leucine, L-Lysine monohydrochloride, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Aspar-
agine, L-Cystine dihydrochloride and L-Glutamine) were purchased from Sigma. Relative cell size was measured after 48 h of culture
on a FACS Verse analyzer.
For ABT-737 (inhibitor of BCL-2, BCL-XL and BCL-W) sensitivity and growth factor deprivation assays, splenic B cells were first
positively selected via magnetic separation as described above. Magnetically purified splenic B cells were then stained with fluores-
cently labeled antibodies directed against CD21, CD23, CD93 and Streptavidin. Fo B cells andMZ B cells were then FACS-sorted as
CD19+ CD93- CD21+ CD23+ and CD19+ CD93- CD21high CD23low, respectively.
For ABT-737 sensitivity assays, sorted Fo andMZB cells were plated in 96well plate U bottom plates in the high-glucose version of
DMEM supplemented with 250 mM L-asparagine (Sigma), 50 mM 2-ME (Sigma) and 10% fetal calf serum in the presence or absence
of 10 mM ABT-737 (Active Biochem). The next day, 104 APC-conjugated CaliBRITE beads (BD Biosciences) and PI (20 mg/mL) were
added to each well before acquisition of data on a FACS Calibur analyzer for quantification of viable cells.
For GFD assays, FACS-sorted Fo and MZ B cells from Ly5.2+ Bak1/ Baxfl/fl CD23-Cre and Ly5.1+ WT origin were mixed and
plated in 96 well plate U bottom plates in complete DMEM (GIBCO) supplemented with 2% BSA. The same day and for the consec-
utive three days, quantification of viable cells was performed on a FACS Verse analyzer after addition to each well of 104 APC-con-
jugated CaliBRITE beads, PI and antibodies against CD45.1.
Deletion of the floxed Bax allele
For assessing the deletion of the floxed Bax allele, transitional and mature B cells were FACS-sorted from the spleen as T1
(CD19+CD93+ IgMhigh CD23low), T2 (CD19+CD93+IgMhighCD23+), T3 (CD19+ CD93+IgMlow CD23+), Fo (CD19+CD93- CD21+
CD23+) and MZ (CD19+CD93-CD21highCD23low) B cells. Sorted subsets were used for genomic DNA extraction with QIAmp DNA
blood Mini Kit (QIAGEN). PCR analysis was performed on 10 ng of gDNA per sample using the DreamTaq Green PCR Master Mix
(Thermo Fisher) under the following conditions: 10 min at 95C, followed by 30 cycles of 30 s at 95C, 30 s at 55C, and 55 s at
72C. The following primers (FWD-Bxfl ACTAGGCCCGGTCCAAGAAC and RVS-Bxfl GAATGCCAAAAGCAAACAGACC) amplified
a 350 bp fragment specific for the undeleted floxed Bax allele. The primer (RVS-del GGCCCCCAAAACTCAGCTAC) used in combi-
nation with FWD amplified a 863 bp fragment which was specific for the deleted floxed Bax allele.
Transcriptome analyses
Only males were used for isolating cells for transcriptome analysis. BM suspension isolated from tibia and femur of mice were labeled
with biotinylated antibodies against CD19 (BD Biosciences) followed by magnetic anti-Biotin beads (Miltenyi Biotech). B cells weree5 Cell Reports 36, 109430, July 20, 2021
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Fo B lymphoctes were flow sorted as B220highIgM+CD93- and were routinely > 99.8% pure. Total RNA was extracted using the
RNeasy extraction Mini kit (QIAGEN). The purity of the RNA samples was assessed by Tape station (Agilent). Samples were prepped
for RNA-seq analysis using Illumina reagents as per the TruSeq RNA sample preparation v2 Guide (Low Sample 23 Protocol). The
completed library was then assessed for quality using the Tape Station (Agilent) and samples were pooled and run on a miSeq
sequencer (Illumina).
Bioinformatics analysis
3 RNA preparations isolated from 3 individual mice were processed for each genotype (Bak1/Baxfl/fl and Bak1/BaxD/D) together
with 6 other samples that were not used in this study. Sequencing reads were processed using the R programming language (v3.3.1)
and the Rsubread software package (v1.20.3) (Liao et al., 2013). Paired-end reads were aligned to the mm10 genome using the sub-
junc function, and then summarized into gene-level counts by the featureCounts function (argument isPairedEnd = TRUE and using
in-built mm10 gene annotation). Differential gene expression analysis was then carried out on the counts using an updated version of
R (v4.0.1), for reference chromosomes only (chr 1 to 19, and chr X and Y). The counts were pre-processed by keeping only genes
(12,677) that were expressed (counts-per-million > 1) in at least 3 samples, and then normalized using the TMM method (Robinson
and Oshlack, 2010) in the calcNormFactors function of edgeR v3.30.3 (McCarthy et al., 2012; Robinson et al., 2010). A mixed effects
model was fitted to the counts using limma v3.44.1 (Ritchie et al., 2015), with biological groups as fixed effects and sample collection
date as random effects.
Briefly, this involved the calculation of precision weights by the voom function (Law et al., 2014), which were then inserted into a
calculation of correlation for sample collection date using the duplicateCorrelation function. Both functions were run twice with the
insertion of correlation or weight estimates from the previous step. The final model found 251 genes (including Bax) to be downregu-
lated between apoptosis refractory and control samples, and 195 genes to be upregulated (adjusted p value cutoff of 5%). For this
comparison, we tested whether any ‘‘biological process’’ GO terms have been over-represented using the goana function (Young
et al., 2010) in limma. Roast gene set testing (Wu et al., 2010) was also carried out for select gene sets from the Molecular Signatures
Database version 7.1, where mouse orthologs were downloaded from http://bioinf.wehi.edu.au/MSigDB/. Barcode plots from limma
were used to give a visual representation of whether a gene set is enriched in our data. In the plots, geneswere ranked by their moder-
ated t-statistics for the comparison between cKOandBak1/Baxfl/fl control samples (the blue sectionmarks negative values and the
red sectionmarks positive values). Vertical black barsmark the presence of genes that belong to the gene set, where the curve above
the barplot indicates an enrichment of genes from the gene set (or high density of black bars) if its value is high.
Raw and processed RNA-seq data are available from GEO under accession number GSE158475.
ELISA
Quantification of BAFF serum levels was performed by using the Mouse BAFF Quantikine ELISA Kit (R&D Systems) following the
manufacturer’s instructions. For detection of NP-specific antibodies, 96-well high binding plates (Sarstedt) were coated overnight
at 4C with 5 mg/mL of NP12-BSA for IgG3 antibodies or NP9-BSA for IgM antibodies. Plates were blocked the following day for
1 h with PBS-1%BSA, washed with PBS-Tween and distilled water and then loaded, in duplicate, with serum samples from mice
immunized with NP-Ficoll. Samples were serially diluted in PBS-1%BSA and incubated for 4 h at 37C. Plates were then washed
in PBS-Tween and distilled water before incubating for 1 h with either IgG3-specific or IgM-specific anti-mouse secondary antibody
conjugated to horseradish peroxidase (Southern Biotech). After a final wash with PBS-Tween and distilled water, plates were devel-
oped with OPD-substrate solution (Sigma Aldrich).
ELISpot
Multiscreen HA plates (Millipore) were coated overnight at 4C, with 10 mg/mL of NP12-BSA for IgG3+ secreting cells or NP9-BSA for
IgM+ secreting cells. Plates were blocked the following day for 1 h with PBS-1%BSA and then washed with PBS. 105 splenocytes
from each mouse were loaded into the plates in duplicate in RPMI-5%FCS, 50 mM 2-ME and 2 mMGlutamine. The plates were incu-
bated overnight at 37C, washed the following daywith PBS-Tween and distilled water and incubated for 1 h at 37Cwith either IgG3-
specific or IgM-specific anti-mouse secondary antibody conjugated to alkaline-phosphatase (Southern Biotech). Plates were
washed with PBS-Tween and distilled water and developed with the BCiP/NBT reaction (Sigma-Aldrich).
Immunofluorescence
Seven-micrometer acetone-fixed spleen sections were incubated with goat serum and then with purified rat anti-IgM (clone II/41, BD
PharMingen). Anti-IgM antibody was detected with a donkey anti-rat Alexa 488 antibody (Invitrogen). Sections were then incubated
with rat serum (Sigma) and subsequently with purified rabbit anti-CD21 (clone SC0681, Invitrogen) and biotinylated rat anti-IgD
(Clone 11-26, Origene) antibodies. Anti-IgD and anti-CD21 antibodies were detected with Streptavidin Alexa 568 (Invitrogen) and
donkey anti-rabbit Alexa 647 (Invitrogen), respectively. Images were captured on a Zeiss LSM 980 Confocal Microscope and
analyzed with ImageJ software.Cell Reports 36, 109430, July 20, 2021 e6
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Statistical analyses were performed using Prism software (GraphPad). P values were calculated by Student unpaired t test with
Welch’s correction or by Mann-Whitney nonparametric, two-tailed test as indicated in figure legends. P values are indicated as fol-
lows: (*) p < 0.05; (**) p < 0.01; (***) p < 0.001 and (****) p < 0.0001. p > 0.05 is indicated as ‘‘NS’’ (not significant). Variables and sample
sizes are indicated in the figure legend.e7 Cell Reports 36, 109430, July 20, 2021
